Last Posted: Aug 21, 2020
- Polygenic background modifies penetrance of monogenic variants for tier 1 genomic conditions
AC Fahed et al, Nature Communications, August 20, 2020 - Bypassing the LDL Receptor in Familial Hypercholesterolemia.
Kersten Sander et al. The New England journal of medicine 2020 Aug (8) 775-776 - Evinacumab for Homozygous Familial Hypercholesterolemia.
Raal Frederick J et al. The New England journal of medicine 2020 Aug (8) 711-720 - Identification of Undetected Monogenic Cardiovascular Disorders.
Abdulrahim Jawan W et al. Journal of the American College of Cardiology 2020 Aug 76(7) 797-808 - Long term follow-up of genetically confirmed patients with familial hypercholesterolemia treated with first and second-generation statins and then with PCSK9 monoclonal antibodies.
Pasta Andrea et al. Atherosclerosis 2020 Jul 3086-14 - 2020 FH Global Summit
The FH Foundation, August 2020 - Genetic Diagnosis of Familial Hypercholesterolemia in Asia.
Huang Chin-Chou et al. Frontiers in genetics 2020 11833 - Polygenic Contribution to Low-density Lipoprotein Cholesterol Levels and Cardiovascular Risk in Monogenic Familial Hypercholesterolemia
M Trinder et al. Cir Genomics Precision Medicine, August 2020 - Awareness, treatment rates, and compliance to treatment in patients with serum LDL cholesterol higher than 250 mg/dl, and possible, probable or definite familial hypercholesterolemia.
Yaman Samet et al. Postgraduate medicine 2020 Aug - Mutation spectrum and polygenic score in German patients with familial hypercholesterolemia.
Rieck Lorenz et al. Clinical genetics 2020 Aug
.png)
No hay comentarios:
Publicar un comentario